Alterity Therapeutics to Present New Data at the Upcoming

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to...

Related Keywords

Colorado ,United States ,San Francisco ,California ,Melbourne ,Victoria ,Australia ,Denver ,Americans ,American ,Danielo Claassen ,Remy Bernarda ,Hannah Howlett ,Daniel Claassen ,Margaret Bradbury ,David Stamler ,European Commission ,Vanderbilt University ,National Institute Of Health ,Parkinson Foundation ,American Academy Of Neurology ,Alterity Therapeutics ,International Conference ,Vanderbilt University Medical Center ,Nasdaq ,Nonclinical Development ,Positive Efficacy Data ,Primate Model ,Baseline Biomarker Data ,American Academy ,Chief Executive Officer ,Novel Inhibitor ,Synuclein Aggregation ,Multiple System Atrophy ,Plight Chain ,Clinical Progression ,Early Multiple System ,Vanderbilt University Medical ,Clinical Phase Small Molecule ,Moderate Affinity ,Disease Model ,Vice President ,System Atrophy ,Neurological Disorders ,Disease Information Page ,Multiple System ,Media Contacts ,Securities Act ,Australian Stock Exchange Ath Ax ,Alterity Therapeutics Limited ,Eurology ,Preclinical Research ,